Abbott Laboratories raised its quarterly dividend 6.8 percent to $0.63 per share on December 12, 2025, extending one of the longest active dividend growth streaks in the S&P 500. The increase brings the annualized payout to $2.52 and marks 54 consecutive years of dividend growth for the diversified healthcare company.
The setup
Abbott announced the dividend increase alongside full-year guidance that pointed to steady growth in its medical devices, diagnostics, and nutrition segments. The 6.8 percent hike outpaces recent increases from peers in the healthcare sector, including Becton Dickinson’s 1 percent raise and Medtronic’s more modest adjustments.
The company generates revenue from products that hospitals and consumers buy repeatedly. Freestyle glucose monitors, Ensure nutrition products, and cardiovascular devices produce recurring demand that supports predictable cash flows. This stability underpins the board’s confidence in raising the dividend at an above-average rate.
Key numbers
| Metric | Value |
|---|---|
| Old quarterly dividend | $0.59 |
| New quarterly dividend | $0.63 |
| Increase percentage | 6.8% |
| New annualized dividend | $2.52 |
| Consecutive years of increases | 54 |
| Announcement date | December 12, 2025 |
What to watch
Abbott’s medical device segment faces competition from Dexcom and other continuous glucose monitoring providers. Pricing pressure in diabetes care could compress margins over time. The nutrition segment also faces shifting consumer preferences that may affect growth rates.
Foreign exchange is another variable. Abbott derives a significant portion of revenue from international markets. A stronger dollar reduces the dollar value of overseas sales. Investors should watch management’s commentary on currency headwinds during upcoming earnings calls.
Per-portfolio income impact
| Investment Amount | Annual Dividend at $0.63/Quarter |
|---|---|
| $100,000 | Approximately $2,100-$2,600 |
| $250,000 | Approximately $5,250-$6,500 |
| $500,000 | Approximately $10,500-$13,000 |
How Abbott compares to healthcare dividend peers
| Company | Ticker | Recent Increase | Annualized Dividend | Years of Growth |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 6.8% | $2.52 | 54 |
| Becton Dickinson | BDX | 1.0% | $4.20 | 54 |
| Medtronic | MDT | Minor | $2.88 | 49 |
| Johnson and Johnson | JNJ | 5.0% | $4.96 | 64 |
Bottom line
Abbott Laboratories delivered a meaningful dividend increase that outpaces most healthcare peers. The 6.8 percent raise reflects confidence in recurring revenue streams and disciplined capital allocation. For income investors building a defensive portfolio, ABT offers a rare combination of dividend growth longevity and above-average percentage increases. The 54-year streak is not guaranteed to continue, but the underlying business model supports the board’s optimistic posture.
Why dividend growth matters for retirees
Dividend growth stocks serve a specific purpose in conservative portfolios. Unlike bonds, which pay fixed coupons, dividend growers increase their payouts over time. For a retiree with $500,000 in dividend growth stocks yielding 3.5 percent initially, a 1 percent annual dividend increase translates to roughly $175 more income in year one. Over a 20-year retirement, the cumulative effect of consistent dividend growth can meaningfully offset inflation.
How Abbott compares to other healthcare Aristocrats
| Company | Ticker | New Quarterly Dividend | Yield (approx) | Consecutive Years |
|---|---|---|---|---|
| Abbott Laboratories | ABT | $0.63 | ~2.1% | 54 years |
| Johnson & Johnson | JNJ | $1.06 | ~2.8% | 64 years |
| Medtronic | MDT | $0.72 | ~3.2% | 49 years |
| Becton Dickinson | BDX | $1.05 | ~1.6% | 54 years |
Compared to higher-yielding alternatives, ABT’s 2.1 percent yield looks modest. But the company’s earnings power and low payout ratio suggest room for continued increases. Income investors who prioritize total return over current yield may find the stock fits well in a diversified portfolio.
Risks to watch
Three factors could pressure ABT’s dividend trajectory. First, generic competition in the pharmaceuticals segment could compress margins. Second, the medical device segment faces pricing pressure as hospitals control spending. Third, foreign exchange volatility affects reported revenue since Abbott derives significant sales outside the United States. Investors should monitor quarterly earnings for organic revenue growth and free cash flow coverage of the dividend.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
